← SynDRA
EDARAVONE
SynDRA canonical compound SYN0002112 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | BCL2 |
|---|
| Mechanism of action | nootropic agent |
|---|
| Indication | stroke |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
Mechanisms of action (all sources)
- nootropic agent
- BCL2 REGULATOR (UPREGULATOR)
Drug classes
- Antioxidants
- Central Nervous System Agents
- Free Radical Scavengers
- Neuroprotective Agents
- Protective Agents
ATC classes
- N07X · OTHER NERVOUS SYSTEM DRUGS
Cross-references
Synonyms
- radicava
- edarabone
- methylphenylpyrazolone
- norantipyrine
- norphenazone
- radicut
- Edaravona
- Norphenazone
- C.i. developer 1
- Colorex pmp
- Developer z
- Jarocol pmp
- Phenyl methyl pyrazolone
- MCI-186
- NSC-12
- NSC-26139
- NSC-2629
- Radicava
- Radicava ors
- Radicut
- Antipyrine related compound a
- MCI 186
- Edarabone
- Methylphenylpyrazolone
- Monopyrazolone
- Norantipyrine
- Phenylmethylpyrazolone
- Developer Z
- Edaravone [INN]
- CDS1_000986
- CI Developer 1
- IN1263
- M0687
- Edaravone(jan)
- Radicut (TN)
- AE-641/00371017
- C.I. Developer 1
- Edaravone (JAN/INN)
Reported adverse events
- Dermatitis
- Eczema
- Gait disturbance
- Glycosuria
- Headache
- Hypersensitivity
- Respiratory failure
- Contusion
- Tinea infection
Look up EDARAVONE in the interactive SynDRA portal →